Clinical trial · Interventional
Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma
Analysis of the Immune Parameters Involved in the Onset and Fate of SARS-CoV-2 Infection in Patients With Multiple Myeloma (COVIMMUNOMM) COVID-19 and Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Recruitment delay due to difficulties to involve patient at Covid diagnosis in hematology departments Abandoned study
Summary
Brief summary (as posted)
Among all MM patients included in the cohort at the time of diagnosis of SARS-CoV-2 infection, blood samples will be collected at inclusion, at time of the infection acute phase in the most severe cases (when admitted in intensive care units), and at recovery. The following immune function tests will be evaluated, gammaglobulin measurements, lymphocytes counts, B, T, and NK cells analyses by cytometry, including exhaustion analyses. In addition, T cell repertoire sequencing looking for SARS-CoV-2- specific T cells, and serologies, will be evaluated at recovery and 6 months after MM treatment re-initiation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Covid19 | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sample analyses | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- blood samples
- description
- 4 blood samples per patient maximum (at diagnosis of covid19, during intensive care if applicable, at revecory of covid 19 and 6 months after recovery.
- interventionNames
- Other: blood sample analyses
Primary outcomes (7)
- measure
- Characterize the immune laboratory parameters of Multiple Myeloma patients at the start of infection with COVID-19
- timeFrame
- up to one month following COVID-19 diagnosis
- description
- gammaglobulin measurements in g/L
- measure
- Characterize the immune laboratory parameters of Multiple Myeloma patients at the cure of COVID-19
- timeFrame
- one month following COVID-19 diagnosis
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 110 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a multiple myeloma and a documented COVID19 (by RT-PCR, thoracic TDM, and/or antigenix test). * Patients having received the information to participate in the research and having expressed their non-opposition * Patients with social security insurance or equivalent Exclusion Criteria: * Patients without multiple myeloma * Patients without COVID19 * Patients under juridical protection guardianship, or tutelage measure
References
Publications (0)
Data not yet available